Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia

• Published in: Journal of clinical lipidology Vol. 10; no. 4; pp. 905 - 914
• Main Authors: Maki, Kevin C., PhD, FNLA, Guyton, John R., MD, FNLA, Orringer, Carl E., MD, FNLA, Hamilton-Craig, Ian, MBBS, PhD, Alexander, Dominik D., PhD, MSPH, Davidson, Michael H., MD, FNLA
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2016
• Subjects: Cardiovascular; Cardiovascular disease; Cardiovascular Diseases - complications; Cardiovascular events; Fibrates; Humans; Hypertriglyceridemia; Hypertriglyceridemia - complications; Hypertriglyceridemia - drug therapy; Hypertriglyceridemia - metabolism; Hypolipidemic Agents - pharmacology; Hypolipidemic Agents - therapeutic use; Lipid-altering drug therapy; Niacin; Omega-3 fatty acids; Risk; Triglyceride-lowering therapy; Triglycerides - metabolism; Cardiovascular events; Hypertriglyceridemia; Cardiovascular disease; Triglyceride-lowering therapy; Fibrates; Niacin; Omega-3 fatty acids; Lipid-altering drug therapy
• ISSN: 1933-2874; 1876-4789
• DOI: 10.1016/j.jacl.2016.03.008

Background Cardiovascular outcomes trials of fibrates, niacin, or omega-3 fatty acids alone, or added to a statin, have not consistently demonstrated reduced risk, but larger, statistically significant clinical benefits have been reported in subgroups with elevated triglycerides (TG) and/or elevated TG plus low high-density lipoprotein cholesterol (HDL-C). Objective To perform a meta-analysis of the effects of therapies targeting TG and TG-rich lipoprotein cholesterol on cardiovascular disease event risk in subjects with elevated TG or elevated TG paired with low HDL-C. Methods Publications were identified using PubMed, the Cochrane Central Register of Controlled Trials, clinicaltrials.gov , the World Health Organization International Clinical Trials Registry Platform, and Internet Stroke Center. Random-effects meta-analysis models were used to generate summary relative risk estimates and 95% confidence intervals. Heterogeneity was assessed by χ2 and I2 statistics, and the impact of each trial was assessed in one study–removed sensitivity analyses. Results Six trials of fibrates, 2 of niacin, 1 of fibrate + niacin, and 1 of omega-3 eicosapentaenoic acid ethyl esters were identified. For the prespecified primary cardiovascular disease or coronary heart disease end point used in each trial, the summary relative risk estimate (95% confidence interval) for subjects with elevated TG was 0.82 (0.73–0.91), p-heterogeneity = 0.13, I2  = 36.2, and for subjects with elevated TG and low-HDL-C, it was 0.71 (0.63–0.81), p-heterogeneity = 0.52, I2  = 0.0. There was no evidence of publication bias, and the results remained statistically significant when each individual trial was removed. Conclusion Drugs that substantially, but not exclusively, lower TG and TG-rich lipoprotein cholesterol may have cardiovascular benefits in individuals with elevated TG, particularly if accompanied by low HDL-C.